<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1084">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563627</url>
  </required_header>
  <id_info>
    <org_study_id>8668</org_study_id>
    <nct_id>NCT01563627</nct_id>
  </id_info>
  <brief_title>Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy</brief_title>
  <official_title>Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy: New Targets for Diagnosis and Prediction of Drug Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epilepsy affects 0.7% of the general population and 15-20% of patients develop drug
      resistance. The temporal lobe epilepsy (TLE) is the most common symptomatic focal epilepsies
      with a particularly high rate of drug (about 20 to 30%). In this type of epilepsy, where
      feasible, surgical removal of the home is the best therapeutic outcome.

      Mechanisms of epileptogenesis and drug resistance are still mysterious. Of recent clinical
      and experimental studies have shown that dysfunction of the blood-brain barrier (BBB)
      contributes to epileptogenesis and drug resistance. It is now recognized that cytokines
      exacerbate the excitability and permeability of the BBB, which was recently confirmed by
      studies showing that treatment of inflammation reduces epileptogenesis. Moreover, we have
      described an association between pathological angiogenesis and BBB permeability in the
      tissue of patients with excision of drug-resistant TLE. With experimental models, it was
      revealed an activation of the VEGF-VEGFR2 by seizures leading to rapid degradation of the
      BBB.

      The investigators hypothesis is that the identification of factors involved in BBB
      permeability may designate potential targets for drug-resistant partial epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Comparison of Biomarkers</measure>
    <time_frame>12 months after inclusion (day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Identify blood sampling biomarkers of drug resistance in temporal lobe epilepsy, an analysis by large-scale expression profiling of serum factors involved in inflammation, immunity and angiogenesis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>permeability of the blood-brain barrier</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare changes in lesion morphologic imaging and blood flow measurements by Magnetic Resonance Imaging between the two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Antiepileptic Drug resistant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients suffering from epilepsy drug-resistant and potentially surgical candidates</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiepileptic drug Controlled group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epilepsy well controlled by antiepileptic drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling for drug resistance biomarkers</intervention_name>
    <description>comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy</description>
    <arm_group_label>Antiepileptic Drug resistant</arm_group_label>
    <arm_group_label>Antiepileptic drug Controlled group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <arm_group_label>Antiepileptic Drug resistant</arm_group_label>
    <arm_group_label>Antiepileptic drug Controlled group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with temporal lobe epilepsy (TLE)

          -  Patient with epilepsy for at least two years. Arm 1: Patient with drug-resistant TLE
             proved potentially a candidate for surgery.

        Arm 2: Patient with TLE seizure-free for 12 months or more

        Exclusion Criteria:

          -  Patient with a scalable general pathology may lead to increased inflammatory markers:
             neoplasia, chronic inflammatory diseases etc. ...

          -  Patient with neurological history other than epilepsy with evolutionary potential or
             likely to interfere with the inflammatory markers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arielle CRESPEL, MD</last_name>
    <phone>04 67 33 72 40</phone>
    <email>a-crespel@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arielle CRESPEL, MD</last_name>
      <phone>04 67 33 72 40</phone>
      <email>a-crespel@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Arielle CRESPEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe GELISSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 13, 2015</lastchanged_date>
  <firstreceived_date>March 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
